Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Other Events

Item 8.01 Other Events

On June26, 2017, Esperion Therapeutics,Inc. issued a press
release titled, Esperion Announces FDA Confirmation of Regulatory
Pathway to Approval for the Combination of Bempedoic Acid and
Ezetimibe (the Press Release). A copy of the Press Release is
filed herewith as Exhibit99.1 and is incorporated herein by
reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

***

Esperion Therapeutics, Inc. Exhibit
EX-99.1 2 a17-15751_1ex99d1.htm EX-99.1 Exhibit 99.1     Media Contact: Elliot Fox W2O Group 212.257.6724 [email protected]   Investor Contact: Mindy Lowe Esperion Therapeutics,…
To view the full exhibit click here
About Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Recent Trading Information

Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed its last trading session down -1.47 at 42.87 with 1,174,636 shares trading hands.